CSO joins during period of growth

CRO Veramed has announced the appointment of Karen Curran as Chief Strategy Officer at a time of substantial global growth for the organisation, which operates as a partner for the whole biometrics value chain, including statistical consultancy, data management, FSP services, clinical trial reporting and automation, DMC and evidence and value generation.

With over 25 years’  experience in the industry, Karen’s role with the specialist biometrics CRO will be to work closely with pharmaceutical and biotech companies to establish innovative data management, statistics and statistical programming partnerships.

Recognised as an industry leader with ability to develop and expand pharmaceutical services businesses globally, her deep market knowledge enables her to provide strategic guidance and devise inventive solutions for biometric processes, including CDISC adoption and implementation, across large and small pharma and CRO environments. She has a track record of supporting successful submissions to regulatory bodies such as the FDA, EMEA and the PMDA. Karen actively contributes to the Global Healthcare Data Science Community Hub PHUSE and currently serves on the CDISC Board of Directors.

“I’m thrilled to have joined Veramed at such an exciting stage of growth,” said Karen. “I look forward to collaborating with our clients and partners to pioneer innovative solutions that meet both short and long-term goals, leading to more efficient and meaningful partnership models.”

Matt Jones, Co-Founder and CEO of Veramed, expressed his enthusiasm about Karen joining the team: "We're excited to have Karen on board as Chief Strategy Officer as we solidify our position as the industry’s CRO of choice."

More information online